Evidence map›Paper›PMID 37440082›Full record

ArticleAdvances in experimental medicine and biology2023

Understanding Ischemic Retinopathies: The Role of Succinate and Its Receptor in Retinal Pigment Epithelium.

Bilge Esin Ozturk

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Bilge Esin OzturkDepartment of Ophthalmology, University of Pittsburgh, Pittsburgh, PA, USA. beo20@pitt.edu.
University of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinopathy is the general name for all condition of the eyes in which blood vessels that supply oxygen to the retina are damaged. These include diabetic retinopathy, retinopathy of prematurity, hypertensive retinopathy, and arteriosclerotic retinopathy. Although the initial trigger that leads to insufficient perfusion of the retina may be different, once a critical level of ischemia is achieved, all types of retinopathies seem to follow a common sequence-oxidative stress, followed by hypoxia-induced formation of morphologically abnormal vessels. This preretinal vascular growth is the most severe aspect of the retinopathy, as the outcome is often retinal detachment and eventually blindness. Regardless of which therapy strategy is followed, a deeper understanding of both normal retinal growth and the underlying molecular mechanisms of retinopathies is needed in order to come up with more effective therapies. This chapter focuses on the citric acid cycle intermediate succinate and its G protein-coupled receptor SUCNR1 in ischemic retinopathies, which were identified as potent mediators of vessel growth in the settings of both normal retinal development and proliferative ischemic retinopathies.

Indexed as

Retinal DiseasesRetinal Pigment EpitheliumHumansInfant, NewbornIschemiaRetinaRetinal VesselsSuccinic AcidSuccinic AcidG protein-coupled receptor GPR91HypoxiaIschemic retinopathiesRetinal pigment epitheliumSuccinate

Identifiers

PMID37440082
OpenAlexW4384120643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.